SCHEDULE 13G/A: BML Investment Partners and Braden Leonard Amend Athira Pharma Stake, Correcting Ownership Details

BML Investment Partners, L.P. and Leonard Braden Michael have filed an amended Schedule 13G, correcting their beneficial ownership of Athira Pharma Inc. common stock to 7.8% as of December 31, 2024.

Summary

• BML Investment Partners, L.P. and Leonard Braden Michael filed an Amendment No. 2 to their Schedule 13G for Athira Pharma Inc. common stock.
• The amendment was filed to correct previously reported share counts and percentage ownership.
• As of December 31, 2024, BML Investment Partners, L.P. beneficially owns 2,775,885 shares, representing 7.2% of Athira Pharma Inc.'s common stock.
• Leonard Braden Michael beneficially owns an aggregate of 3,027,163 shares, representing 7.8% of Athira Pharma Inc.'s common stock.
• Of Leonard Braden Michael's total, 251,278 shares are held with sole voting and dispositive power, while 2,775,885 shares are held with shared voting and dispositive power.
• The filing states that the securities were not acquired or held for the purpose of changing or influencing the control of Athira Pharma Inc.
• Braden M. Leonard is deemed an indirect owner of shares held by BML Investment Partners, L.P. due to his role as managing member of BML Capital Management, LLC, the general partner of BML Investment Partners, L.P.

Sentiment

Score: 5

Explanation: The sentiment is neutral as this is a factual filing to correct previously reported beneficial ownership information, with no indication of positive or negative operational or financial performance.

Future Outlook

NA

Management Comments

• "This amendment was filed to correct the share count and percentage ownership."
• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11."
• "Despite such shared beneficial ownership, the reporting persons disclaim that they constitute a statutory group within the meaning of Rule 13d-5(b)(1) of the Exchange Act."

Industry Context

This filing is a routine disclosure of beneficial ownership, common in the investment industry, and does not provide specific insights into broader industry trends or competitive landscape beyond the fact that an investment firm holds a significant stake in a pharmaceutical company.

Stakeholder Impact

• Shareholders: Provides updated and corrected information regarding significant beneficial ownership, offering clarity on the ownership structure of Athira Pharma Inc.

Key Dates

Keywords

Athira Pharma Inc., BML Investment Partners, Leonard Braden Michael, Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing, Investment, Shareholding